3218 results for «500»
3218 results
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
PCR Tokyo Valves 2026 Welcome Ceremony
14 Feb 2026 – From PCR Tokyo Valves 2026
The Welcome Ceremony marks the commencement of the conference, setting the stage for an engaging and informative program dedicated to advances in cardiology and interventional techniques. It provides attendees with an overview of the event's objectives and highlights the collaborative spirit of the cardiology community.
Plaque modification in different lesions types: nodular, long lesions, tortuous lesions, bifurcations
28 Feb 2026 – From Euro4C Annual Meeting 2026
Explore advanced plaque modification strategies tailored to diverse lesion types such as nodular, long, tortuous lesions, and bifurcations. Delve into approaches for managing under-expanded stents and calcified nodules, supported by evidence including results from the French orbital atherectomy registry.
How to avoid and manage complications
28 Feb 2026 – From Euro4C Annual Meeting 2026
Build a comprehensive complication-management toolbox tailored for PCI in heavily calcified vessels. This session covers prevention and management techniques for complications arising from severely calcified lesions, illustrated by practical cases and expert insights into risky lesions and challenging devices.
Drug-eluting balloon in calcified lesions and complex lesions
28 Feb 2026 – From Euro4C Annual Meeting 2026
This session explores the application of drug-eluting balloons (DCB) in managing calcified and complex coronary lesions. Emphasis is placed on identifying appropriate lesions for a DCB-only strategy, the critical role of vessel preparation prior to drug delivery, and the long-term physiological assessment following treatment, supported by...
Closing Ceremony
28 Feb 2026 – From Euro4C Annual Meeting 2026
The closing ceremony marks the conclusion of the conference, providing a summary of key learnings, acknowledgments, and final reflections on the advancements and discussions presented throughout the event.
Learn from the experts: Evolut first implant technique and treatment strategies
15 Feb 2026 – From PCR Tokyo Valves 2026
This expert-led session offers an in-depth review of evolving clinical practices in aortic valve disease treatment, emphasizing the potential of the transcarotid approach as a primary alternative access route. It compares current strategies including TAVI, surgical aortic valve replacement (SAV), TAV-in-SAV, and TAVI explantation, while addressing...
Learn from the experts: lifetime management for Evolut first redo TAVI (TAV-in-TAV) and explant
14 Feb 2026 – From PCR Tokyo Valves 2026
This session offers an in-depth exploration of lifetime management strategies for patients undergoing Evolut first redo TAVI procedures, including TAV-in-TAV and explant techniques. It provides a comprehensive understanding of clinical decision-making algorithms, technical challenges, and key considerations for successful procedural planning and execution, supported by real-world...
Real world outcomes and strategies for optimal TEER across diverse DMR anatomies
14 Feb 2026 – From PCR Tokyo Valves 2026
This session develops a nuanced understanding of the complexity inherent in DMR cases, informed by the latest registry data. It highlights the capabilities of the PASCAL device in managing challenging anatomies and achieving predictable clinical results, alongside contemporary strategies for device selection and optimal placement to...
Hotline - Mitral and tricuspid valvular interventions
16 Nov 2025 – From PCR London Valves 2025
This session delves into innovative mitral and tricuspid valvular interventions, highlighting outcomes with the PASCAL precision system and advances in combined MitraClip and TriClip repairs. It discusses predictors of heart failure hospitalization post-transcatheter tricuspid valve repair (TTVR), coronary CT-based pacemaker implantation prediction, and novel devices aimed...
TAVI and coronary artery disease
16 Nov 2025 – From PCR London Valves 2025
This session focuses on the interplay between TAVI and coronary artery disease, discussing high-risk TAVR cases requiring complex left main PCI with prophylactic ECMO support. It provides guidance on timing and strategies for managing concomitant coronary artery disease in TAVI patients, addressing the critical decision-making process...
TAVI: vascular complications
16 Nov 2025 – From PCR London Valves 2025
This session examines vascular complications associated with transfemoral TAVI procedures, featuring challenging cases such as initial procedural obstacles, complex post-TAVI vascular events, and unusual complications. It also explores advanced techniques like intravascular lithotripsy to optimize TAVI outcomes in patients with severe calcific iliofemoral disease.
TAVI: high coronary risk - Part 2
16 Nov 2025 – From PCR London Valves 2025
This session presents advanced strategies to mitigate high coronary risk during valve-in-valve TAVR procedures, including the LLAMACORN technique and chimney stenting to prevent coronary obstruction. It discusses management of misaligned prostheses, complex aortic and coronary anatomies, and innovative approaches such as stent crush techniques to ensure...
Complex mitral and tricuspid TEER
16 Nov 2025 – From PCR London Valves 2025
This session highlights complex cases in mitral and tricuspid transcatheter edge-to-edge repair (TEER), addressing challenges such as septal obstacles in patients with old atrial septal occluders, management of residual atrial septal defects post-mitral valve-in-ring replacement, and innovative multidisciplinary approaches. It also covers hybrid transapical mitral valve-in-valve...
Retrieval of embolised devices
16 Nov 2025 – From PCR London Valves 2025
This session delves into the complex scenarios of embolised device retrieval, exploring various interventions such as management of Lambre device embolisation, alternatives to surgery for superior vena cava baffle stent embolisation, novel strategies for chronically embolised Gore Helex atrial septal occluder device retrieval, and challenging redo...
Late-breaking evidence in structural and coronary interventions - Part 2
16 Nov 2025 – From PCR London Valves 2025
This session presents the latest data from pivotal late-breaking trials in interventional cardiology. Highlights include one-year results from the ADALA trial, first-in-man use of the Vivasure PerQseal Elite for large hole arterial closure, two-year outcomes of the DragonFly system in China, six-month European outcomes, and insights...
PCR London Valves 2025 Welcome Ceremony
16 Nov 2025 – From PCR London Valves 2025
The PCR London Valves 2025 Welcome Ceremony marks the commencement of the conference, setting the stage for an immersive exploration of the latest advances and innovations in valvular heart disease management with a focus on transcatheter interventions.
Redo TAVI with pre and post dilatation - LIVE Case
16 Nov 2025 – From PCR London Valves 2025
Watch this live case followed by a live in a box case, regarding a 93-year-old woman with hypertension, chronic bronchitis, and a history of TAVI with a Sapien 3 23 mm (2016) who presented with symptomatic severe aortic stenosis and mildly reduced LV function (50%). An...
The Silk Road of MedTech
16 Nov 2025 – From PCR London Valves 2025
Discover pioneering MedTech innovations along the Silk Road, including novel sheath designs for minimalist TAVR, self-expanding valves for pure aortic regurgitation, automated CT quantification via deep learning, and first-in-man experiences with cutting-edge valvuloplasty and TEER devices.
Innovations in TAVR: clinical insights and future perspectives
16 Nov 2025 – From PCR London Valves 2025
Presenting featured research on TAVI, this session covers outcomes from centers without on-site cardiac surgery, comparative leaflet modification techniques, conscious sedation protocols, left ventricular health in timing TAVR, and long-term valve durability insights including seven-year follow-up data.
